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Abstract  
BACKGROUND: Chronic Obstructive Pulmonary Disease (COPD) is associated with evidence of 
systemic oxidative stress, activation of circulating inflammatory cells and increased plasma level of 
proinflamatory cytokines which include C-reactive protein (CRP). CRP is one biomarker of 
extrapulmonary or systemic consequences of COPD that can be detected. 
AIM: The aim of this research is to determine whether the level of CRP statistically significantly 
correlates with the level of bronchial obstruction and the accompanying co-morbidities in patients 
with COPD. 
MATERIAL AND METHODS: This study included 80 patients with exacerbation of COPD, 
hospitalised at the Institute for Lung Diseases and Tuberculosis in Skopje. We measured the level 
of CRP in the blood in all of these patients in fasting conditions. The classification of COPD patients 
by the severity of airflow limitation was made according to the actual version of the Global initiative 
for chronic Obstructive Lung Disease (GOLD). The Student’s Independent Samples t-test was used 
for the statistic analysis of the data.  
RESULTS: In 52 (65%) of the patients with exacerbation of COPD we detected an increase of the 
mean value of CRP. The statistical analysis using the Student’s t-test showed statistically significant 
differences in the mean value of CRP in patients with different level of bronchial obstruction. 
Hypertension, heart failure, diabetes mellitus, hyperlipidemia, coronary disease, and CVI were 
confirmed as co-morbidities in 45 (73.1%) of the patients, hypertension being the most frequent one 
(40%). The statistical analysis using the Student’s t-test showed statistically significant difference of 
the mean value of CRP (p< 0.01) depending on the number of co-morbidities. 
CONCLUSION: In 52 (65%) of the patients with exacerbation of COPD, were detected an increase 
of the mean value of CRP. The mean values of CRP statistically significantly correlate with the level 
of bronchial obstruction and the number of co-morbidities in patients with COPD. 
 
 
 
 
 
 
Introduction 
 
Chronic Obstructive Pulmonary Disease 
(COPD) is a major cause of chronic morbidity and 
mortality throughout the world [1].  It is primarily 
characterized by the presence of airflow limitation 
resulting from airways inflammation and remodelling 
often associated with parenchymal destruction and 
development of emphysema [2].  
Increasing evidence suggests that COPD is a 
complex disease involving more than airflow 
obstruction [1]. 
In many patients the disease is associated 
with several systemic manifestations that can 
effectively result in impaired functional capacity, 
worsening dyspnea, and reduced health-related 
quality of life [2, 3]. The most common manifestations 
include the presence of concomitant cardiovascular 
compromise, diabetes, malnutrition involving primary 
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the loss and dysfunction of skeletal muscles, 
osteoporosis, clinical depression and anxiety [3-6]. 
Currently, the GOLD definition of COPD includes the 
words “some significant extrapulmonary effects that 
may contribute to the severity in individual patients“. It 
has suggested that COPD should be renamed a 
“chronic systemic inflammatory syndrome” [7, 8]. 
COPD is associated with evidence of systemic 
oxidative stress, activation of circulating inflammatory 
cells and increased plasma level of proinflamatory 
cytokines which include C-reactive protein (CRP), IL-
6, fibrinogen, leucocytes and TNF [3, 5, 7, 9]. 
Patients with COPD have higher circulating 
levels of IL-6 [2, 7]. This cytokine is a potent stimulator 
of CRP production by the liver and may account for 
the increase in circulating CRP found in patients with 
COPD [2]. It is an acute-phase protein synthesized 
predominantly by the hepatocytes in response to 
tissue damage or inflammation reflecting the total 
systemic burden of inflammation of individuals [5]. 
CRP is one biomarker of extrapulmonary or systemic 
consequences of COPD that can be detected clinically 
and that could also be measured. 
The aim of this research is to determine 
whether the level of CRP in patients with COPD 
statistically significantly correlates with the level of 
bronchial obstruction and the accompanying co-
morbidities.  
 
 
Material and Methods 
 
This study included 80 patients with 
exacerbation of COPD, hospitalised at the Institute for 
Lung Diseases and Tuberculosis. Out of these 80 
patients, 48 were male and 32 were female. We 
measured the level of CRP in the blood in all of these 
patients in fasting conditions.  
The classification of COPD patients by the 
severity of airflow limitation was made according to 
the actual version of the Global initiative for chronic 
Obstructive Lung Disease (GOLD) i.e. GOLD 1, 
GOLD 2, GOLD 3 and GOLD 4 (mild, moderate, 
severe, very severe airways obstruction) [8]. 
Table 1: Measurement of forced expiratory volume in one 
second (FEV1) 
________________________________________________________________________ 
Group          Subjects           Obstruction                       FEV1 
________________________________________________________________________ 
GOLD1         13                   mild                             FEV1≥ 80% predicted 
GOLD2         20                   moderate                     50%≤FEV1< 80% predicted 
GOLD3         32                   severe                         30≤FEV1< 50% 
GOLD4         15                   very severe                  FEV1 ≤ 30% predicted or  
                                                                             FEV1<50% predicted plus  
                                                                             chronic respiratory failure  
________________________________________________________________________ 
The Student’s Independent Samples t-test 
was used for the statistic analysis of the data.  
Results 
 
The mean values of CRP in patients with 
different level of bronchial obstruction are shown in 
Table 2. 
Table 2: Mean values of CRP in patients with COPD 
Group N (number) 
Mean value of CRP 
mg/l ± SD 
t-test p 
GOLD1 13 8.6 ± 5.5 GOLD1/GOLD2 = 2.3 <0.05 
GOLD2 20 17.1 ± 9.8 GOLD1/GOLD3 = 4.9 <0.01 
GOLD3 32 36.7 ± 27.6 GOLD1/GOLD4 = 6.5 <0.01 
GOLD4 15 77.0 ± 38.1 GOLD3/GOLD4 = 3.6 <0.01 
Student’s Independent Samples t-test 
 
The statistical analysis conducted using the 
Student’s t-test showed significant statistical 
differences in the mean values of CRP in patients with 
different level of bronchial obstruction. The highest 
mean value of CRP was registered in patients with 
very severe bronchial obstruction (GOLD 4). 
The frequency and distribution of co-
morbidities in patients with COPD is shown in Figure 
1. 
 
Figure 1: Distribution of co-morbidities 
 
The mean values of CRP in correlation with 
the number of co-morbidities are shown in Table 3. 
Table 3: Mean value of CRP according to the number of co-
morbidities 
Comorbidities N (number) Mean value  of CRP 
mg/l ± SD 
t-test p 
COPD 25 11.6 ± 6.3 COPD/COPD+CoMb1=3.29 <0,01 
COPD+CoMb1  20 26.2 ± 17.8 COPD/COPD+CoMb2=4.42 <0.01 
COPD+CoMb2 20 40.8 ± 31.0 COPD/COPD+CoMb3=4.72 <0.01 
COPD+CoMb3 11 71.4 ± 41.0 COPD/COPD+CoMb4=5.96 <0.01 
COPD+CoMb4 4 92.5 ± 26.8   
The Student’s Independent Samples t-test; COPD +CoMb1 -  COPD plus   one  
comorbidity; COPD+Co Mb2 – COPD plus   two comoprbidities; COPD+Co Mb3 – COPD 
plus   three comoprbidities; COPD+Co Mb4 – COPD plus   four comoprbidities. 
 
The statistical analysis conducted using the 
Student’s t-test showed statistically significant 
increase of the mean value of CRP (p< 0.01) in 
correlation with the number of co-morbidities. 
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Discussion 
 
COPD is a complex disease involving more 
than airflow obstruction [1]. COPD is associated with 
evidence of systemic oxidative stress, activation of 
circulating inflammatory cells and increased plasma 
level of proinflamatory cytokines. Individuals     with 
COPD had significantly raised levels of several 
markers of inflammation which include C-reactive 
protein (CRP), IL-6, fibrinogen, leucocytes and TNF 
[2-5, 7, 9, 10]. Our retrospective study also registers 
increase of the mean value of CRP in 52 (65 %) of the 
patients. 
Rennard and his associates [2] reported on 
the relationship between FEV1 and levels of various 
systemic inflammatory markers such as CRP. This 
analysis indicated that reduced lung function 
significantly correlated with the elevated levels of 
systemic inflammatory markers. 
Nillawar and his associates [10], in their study 
carried out with 45 patients with COPD, point out that 
there is statistically significant increase of the value of 
CRP, whose mean value of FEV 1 was 45.27 % +/-
15%. In our study, in 52 (65%) of the patients with 
exacerbation of COPD, were detected an increase of 
the mean value of CRP.   
The statistical analysis of the mean values of 
CRP using the Student’s t-test showed statistically 
significant increase of the mean values of CRP in 
correlation with the level of bronchial obstruction (Р < 
0.05; P < 0.01). 
In many patients, COPD is associated with 
several systemic manifestations that can effectively 
result in impaired functional capacity, worsening 
dyspnoea, and reduced health-related quality of life [2, 
3]. In our study, hypertension, hеart failure, diabetes 
mellitus, hyperlipidaemia, coronary disease, CVI were 
confirmed as co-morbidities in 45 (73.1%) of the 
patients, hypertension being the most frequent one 
(40%). 
Several studies have demonstrated a strong 
relationship between COPD and cardiovascular 
disease with COPD patients having a two-fold 
increase in risk for morbidity and mortality due to a 
cardiovascular disease [5, 10, 11]. The underlying 
mechanism is still not fully understood. However, 
COPD is recognized as a systemic inflammation 
which might extend beyond the lungs causing other 
co-morbidities. Consequently, the inflammatory state 
in patients with COPD might lead to the development 
of atherosclerosis, which is also known as an 
inflammatory process. It is thought that the 
inflammation observed in COPD patients plays a 
significant role in the pathogenesis of atherosclerosis. 
Furthermore, in patients with both COPD and 
cardiovascular disease, increasing C-reactive protein 
levels are present, which confirms the presence of a 
systemic inflammation [12]. The relationship between 
COPD, systemic inflammation and a cardiovascular 
disease is of particular importance, since more than 
one half of all patients with COPD die due to 
cardiovascular causes. 
Rutten and his associates [13] point out that 
20% of the patients with COPD had a non-diagnosed 
left-sided heart failure. Our study also demonstrates 
23% of left-sided heart failure in patients with COPD. 
Leonardo and his associates [14] indicate that 
20% of the patients had left-sided heart weakness, 
and 50% of the patients had one or more components 
of metabolic syndrome. According to data, the 
prevalence of diabetes in COPD varies from 2% 
(Sidney [15]), 12% (Mapel and associates [16]) to 
16% (Wash and Thomasov [17]). In our study, we 
registered hyperlipidemia in 12.5%, and diabetes in 
15% of the patients. The systematic inflammation 
accounts for the connection between COPD and 
diabetes mellitus type 2. The diabetes is 
independently associated with reduction of the lung 
function, and the frequently common obesity may 
additionally deteriorate the clinical picture in patients 
with COPD. Recent studies suggest that raised level 
of CRP, IL 6 and TNF result in alteration of the 
metabolic processes and resistance to insulin. 
In our study, too, the statistical analysis 
conducted with the Student’s t-test, demonstrated 
statistically significant increase of the mean value of 
CRP (p < 0.01) depending on the number of co-
morbidities. 
In conclusion, in 52 (65%) of the patients with 
exacerbation of COPD, were detected an increase of 
the mean value of CRP. The mean values of CRP 
statistically significantly correlate with the level of 
bronchial obstruction and the number of co-
morbidities in patients with COPD. 
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